Metropolis Healthcare aims to raise EBITDA margins to 27-28% within three years through operational efficiency and volume growth. The strategy focuses on specialty diagnostics and expanding to 1,000 centers without relying on price increases.
Metropolis Healthcare has outlined a new three-year growth plan, setting a target to reach EBITDA margins of 27-28 percent by fiscal year 2029. This goal represents a shift from the company's fiscal year 2026 margin of 24.4 percent. The management has indicated that this margin expansion will be driven by operational efficiencies rather than price hikes, emphasizing a volume-led growth strategy with a targeted annual revenue growth rate of 14-15 percent.
The core of this strategy involves scaling the company’s physical network. Metropolis plans to increase its number of owned centers from the current 750 to 1,000. A major focus for management is optimizing the center-to-lab ratio, which is currently 24:1, and moving it toward 35:1. By achieving this, the company expects to extract more value and higher utilization from its existing laboratory infrastructure without needing to spend excessively on new laboratory setups.
Specialty diagnostics, which includes areas like genomics and oncology, is another pillar of this plan. The company intends to increase the revenue contribution from this high-value segment to 45 percent, up from the current 40 percent. Management also highlighted that recent acquisitions, including those in the oncology space like Core Diagnostics, are expected to move from being loss-making to contributing to the company's overall profitability within the next two years.
Technological investment will also play a key role in the company's efficiency drive. Metropolis is planning an overhaul of its digital infrastructure, including the use of AI-driven automation to streamline workflows. This is intended to boost productivity and handle higher testing volumes without requiring a proportional increase in headcount.
While the company pursues this growth strategy, investors may keep an eye on several industry-wide and company-specific risks. Diagnostic pricing is a sector that frequently faces scrutiny, and potential regulatory caps on testing prices could impact revenue projections. Additionally, the diagnostics industry remains highly competitive, with both large hospital chains and numerous standalone players vying for market share.
Execution will also be a critical factor. The company’s ability to successfully integrate recent acquisitions and scale its operations in smaller towns without compromising on service quality or margins will be closely monitored. As the company funds these initiatives through internal cash reserves and avoids aggressive debt, the next key updates for investors will be the quarterly progress on margin expansion, the pace of center expansion, and the contribution of specialty diagnostics to the top line.